Financials data is unavailable for this security.
View more
Year on year Neurocrine Biosciences Inc grew revenues 26.76% from 1.49bn to 1.89bn while net income improved 61.62% from 154.50m to 249.70m.
Gross margin | 98.28% |
---|---|
Net profit margin | 16.00% |
Operating margin | 25.30% |
Return on assets | 11.46% |
---|---|
Return on equity | 15.55% |
Return on investment | 13.74% |
More ▼
Cash flow in USDView more
In 2023, Neurocrine Biosciences Inc did not generate a significant amount of cash. However, the company earned 389.90m from its operations for a Cash Flow Margin of 20.66%. In addition the company generated 65.30m cash from financing while 467.10m was spent on investing.
Cash flow per share | 3.54 |
---|---|
Price/Cash flow per share | 33.43 |
Book value per share | 24.87 |
---|---|
Tangible book value per share | 24.54 |
More ▼
Balance sheet in USDView more
Current ratio | 4.19 |
---|---|
Quick ratio | 4.08 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 58.26%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years) | 62.04 |
---|---|
EPS (TTM) vs TTM 1 year ago | 90.33 |